Cite
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
MLA
Lynce, Filipa, et al. “Phase I Study of JAK1/2 Inhibitor Ruxolitinib with Weekly Paclitaxel for the Treatment of HER2-Negative Metastatic Breast Cancer.” Cancer Chemotherapy & Pharmacology, vol. 87, no. 5, May 2021, pp. 673–79. EBSCOhost, https://doi.org/10.1007/s00280-021-04245-x.
APA
Lynce, F., Williams, J. T., Regan, M. M., Bunnell, C. A., Freedman, R. A., Tolaney, S. M., Chen, W. Y., Mayer, E. L., Partridge, A. H., Winer, E. P., & Overmoyer, B. (2021). Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemotherapy & Pharmacology, 87(5), 673–679. https://doi.org/10.1007/s00280-021-04245-x
Chicago
Lynce, Filipa, James T. Williams, Meredith M. Regan, Craig A. Bunnell, Rachel A. Freedman, Sara M. Tolaney, Wendy Y. Chen, et al. 2021. “Phase I Study of JAK1/2 Inhibitor Ruxolitinib with Weekly Paclitaxel for the Treatment of HER2-Negative Metastatic Breast Cancer.” Cancer Chemotherapy & Pharmacology 87 (5): 673–79. doi:10.1007/s00280-021-04245-x.